Saturday, January 24, 2009

1:00 pm to 5:00 pm

Registration

Registration packets may be picked up from 1:00 - 5:00 pm, at the Conference Registration desk located on the Ballroom level.

Sunday, January 25, 2009

1:00 pm to 5:00 pm

Registration

5:00 – 8:00 pm

Opening Session

Sunshine Peak/Mt. Werner

SPONSOR: LONZA & ELSEVIER

Total Synthesis of Complex Molecules: from Natural Products to Pharmaceutical Scale up

Tony Barrett, Imperial College – Program Chair

• Viresh Rawal, University of Chicago, Mycalamides, Pederin and Related Natural Products:  Chemical Synthesis and Biological Studies
• David Entwistle  - Pfizer - Process Development and Multi Kilogram Synthesis of Inhaled UK-432,097  
• Sheng Cui, Amgen, Practical Asymmetric Conjugate Alkynylation of Meldrum's Acid Derived Acceptors
• Robert Williams, Colorado State University - HDAC Inhibitors

8:00 – 10:00 pm

Welcome Reception

Storm Peak

Monday, January 26, 2009

8:00 – 11:00 am

Morning Session

Sunshine Peak/Mt. Werner

PK/PD Modeling and Simulation: Opportunities to bridge the Drug Discovery to Drug Development Divide

• Greg Winchell, Merck - PK/PD Modeling and Simulation - Fundamentals and Applications to Drug Development
• Maury Emery, Amgen, PK/PD Modeling in Candidate Selection and Early Development
• Michael Klimas, Merck, Application of Imaging in Translational Drug Discovery and Development
• William Kielbasa, Lilly, An Animal to Human Translational PK-PD Approach Based on Brain Receptor Occupancy To Establish Clinical Dose

4:00 – 8:00 pm

Evening Session

Sunshine Peak/Mt. Werner

Novel Approaches for the Pharmacological Treatment of Pain
 Philippe Nantermet, Merck Research Laboratories – Program Chair

• Darell Henze, Merck – Overview of the Field, Challenges and Opportunities
• Doug Johnson, Pfizer US – FAAH Inhibitors for the Treatment of Pain
• Peter Petillo, Deciphera Pharmaceuticals- Molecular Mechanisms of Acquired Resistance to Kinase Inhibitors
• Puwen Zhang, Wyeth, Synthesis and Activity of 1-(3-amino-2-hydroxy-1-phenylpropyl)Indolin-2-ones and Derivatives:  Discovery of Selective Norepinephrine Reuptake Inhibitor WAY-318068
• Craig Stump, Merck – CGRP Receptor Antagonists as Novel Pain Therapeutics

Tuesday, January 27, 2009

8:00 – 11:00 am

Morning Session

Sunshine Peak/Mt. Werner

FOR THE UNIVERSITY OF KANSAS

The University of Kansas Department of Medicinal Chemistry
Jeff Aube, University of Kansas, Program Chair

• Jane Aldrich - Identification of a Systemically Active Peptidic Kappa Opioid Receptor Antagonist and its Potential Applications
• Brian Blagg - Old Drugs for New Targets: A Case Study with Novobiocin and Hsp90
• Blake Peterson - Synthetic Mimics of Mammalian Cell Surface Receptors: New Tools for Drug Delivery and Probes of Cellular Biology
• Tom Prisinzano - Utilizing Nature as a Source of New Probes for CNS Disorders
• Emily Scott -  Human Cytochrome P450 enzymes: Drug Metabolism and Drug Target

4:30 – 7:30 pm

Evening Session

Sunshine Peak/Mt. Werner

SPONSOR: CHEMDIV

Oral Session I

Mike VanNieuwenhze, Indiana University, Program Chair         

• Sebastian Kroll, Imperial College - Towards the Synthesis of Selective CDK7 Inhibitors as Potential Anti-Cancer Drugs
• Peter G. Ruminski, Pfizer - Design of Orally Active and Highly Specific Matrix Metalloproteinase-13 Inhibitors for the Treatment of Osteoarthritis
• Aiming  Sun Ph.D, Emory University - Discovery of Potent Measles Virus RNA-Dependent RNA Polymerase Inhibitors
• Alexander Khvat, ChemDiv - Discovery of Developmental Pathway Inhibitors: A Case Study for Hedgehog Pathway Modulators
• Scott Webster, University of Edinburgh - The Discovery of Novel Inhibitors of 11b-Hydroxysteroid Dehydrogenase Type 1 (11b-HSD1)
• Mike Shultz, Novartis Institutes for Biomedical Research, Hydroxamate Based Histone Deacetylase Inhibitors with Improved Potency and Reduced Affinity for the hERG Ion Channel.  

SPONSOR: TDC RESEARCH, INC.

Wednesday, January 28, 2009

8:00 – 11:00 am

Morning Session

Sunshine Peak/Mt. Werner

Recent Advances in Understanding and Overcoming Drug Resistance

Daniel Flynn, Deciphera Pharmaceuticals, Program Chair

• Thomas O'Hare, PhD, Oregon Health Sciences University - Predicting and Controlling BCR-ABL Mutation-Mediated Resistance in CML: Cornering an Escape Artist
• Tomasz Skorski, Temple - Oncogenic Tyrosine Kinases Modulate Genomic Stability and Apoptosis to Resist Their inhibitors and Promote Malignant Disease Progression
• Gerry Wright, McMaster University  -  New Mechanisms of Antibiotic Resistance, and Reversing Resistance with Small Molecules
• Shahriar Mobashery, Notre Dame - Resistance to beta-Lactam Antibiotics in Methicillin-Resistant Staphylococcus Aureus (MRSA)

5:00 – 7:00 pm

Poster Session

Storm Peak

Poster Session: Jack Hodges, Berry & Associates, Program Chair

7:00 pm

Keynote Banquet & Address

Sunshine Peak/Mt. Werner

Professor Steven V. Ley, University of Cambridge

Thursday, January 29, 2009

8:00 – 11:00 am

Morning Session

Sunshine Peak/Mt. Werner

SPONSOR: CHEMDIV

Oral Session  II

Mike Rafferty, Deciphera Pharmaceuticals, Program Chair

• Jim Monn, Eli Lilly - Glutamate Receptor Agonist/Antagonists

• Christopher Schnieder, University of Minnesota - Total Synthesis and Analog Development of Oximidine II: Discovery of an Unprecedented Reductive Castro-Stephens Tandem Reaction

• Frank Schoenen, University of Kansas Structural Biology Center - Modular Approach to Compound Libraries Inspired by Martinellic Acid and the Steroid Nuclear Hormones.

• Jeroen  Verheijen, PhD, Wyeth Research - Pyrazolopyrimidines as ATP Competitive, Highly Potent and Selective MTOR Inhibitors for Oncology

• Anthony Lozama, University of Kansas - Novel Opioid Receptor Probes Derived From Structural Modification to the Neo-Clerodane Diterpene

11:00 am 

Meeting Adjourns